Cancer treatment with epothilones

Details Cancer treatment with epothilones Cancer treatment with epothilones

2011-01-25

2011-01-25

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07875601

ABSTRACT:
The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

REFERENCES:
patent: 5716939 (1998-02-01), Lundy et al.
patent: 5969145 (1999-10-01), Schinzer et al.
patent: 6020315 (2000-02-01), Bosslet et al.
patent: 6043372 (2000-03-01), Schinzer et al.
patent: 6121029 (2000-09-01), Schupp et al.
patent: 6156905 (2000-12-01), Schinzer et al.
patent: 6242469 (2001-06-01), Danishefsky et al.
patent: 6284781 (2001-09-01), Danishefsky et al.
patent: 6288237 (2001-09-01), Hoefle et al.
patent: 6300355 (2001-10-01), Danishefsky et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 6348551 (2002-02-01), Fürstner et al.
patent: 6350878 (2002-02-01), Altmann et al.
patent: 6369234 (2002-04-01), Danishefsky et al.
patent: 6380394 (2002-04-01), Nicolaou et al.
patent: 6441186 (2002-08-01), Nicolaou et al.
patent: 6605726 (2003-08-01), Multzer et al.
patent: 6613912 (2003-09-01), Hoefle et al.
patent: 6635666 (2003-10-01), O'Reilly et al.
patent: 6660758 (2003-12-01), Nicolaou et al.
patent: 6828340 (2004-12-01), Danishefsky et al.
patent: 6831076 (2004-12-01), Hoefle et al.
patent: 2001/0034452 (2001-10-01), Hoefle et al.
patent: 2003/0203876 (2003-10-01), Hoogevest
patent: 2003/0203938 (2003-10-01), Nicolaou et al.
patent: 2003/0220295 (2003-11-01), Vite et al.
patent: 2004/0087634 (2004-05-01), Hoefle et al.
patent: 2004/0127432 (2004-07-01), Nicolaou et al.
patent: 2004/0142990 (2004-07-01), Hofmann et al.
patent: 2004/0176429 (2004-09-01), Li et al.
patent: 2004/0253697 (2004-12-01), Julien et al.
patent: 2004/0260098 (2004-12-01), Danishefsky et al.
patent: 41 38 042 (1993-05-01), None
patent: WO 93/10121 (1993-05-01), None
patent: WO 97/19086 (1997-05-01), None
patent: WO 98/25929 (1998-06-01), None
patent: WO 99/01124 (1999-01-01), None
patent: WO 99/02514 (1999-01-01), None
patent: WO 9907692 (1999-02-01), None
Balog et al., Tetrahedron Lett., vol. 38(26), “Stereoselective Syntheses and Evaluation of Compounds in the 8-Desmethylepothilone A Series: Some Surprising Observations Regarding Their Chemical and Biological Properties,” pp. 4529-4532 (1997).
Blagosklonny et al., Cancer Res., vol. 57, “Raf-1/bcl-2 Phosphorylation: A Step from Microtubule Damage to Cell Death,” pp. 130-135 (1997).
Bollag et al., Cancer Res., vol. 55, “Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action,” pp. 2325-2333 (1995).
Bollag, D.M., Exp. Opin. Invest. Drugs, vol. 6(7), “Epothilones: novel microtubule-stabilising agents,” pp. 867-873 (1997).
Chou et al., Proc. Natl. Acad. Sci. USA, vol. 95, “Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B,” pp. 9642-9647 (1998).
Finlay, R., Chemistry & Industry, “Metathesis vs. metastasis: the chemistry and biology of the epothilones,” pp. 991-996 (Dec. 15, 1997).
Gerth et al., J. Antibiotics, vol. 49, “Epothilons A and B: Antifungal and Cytotoxic Compounds fromSorangium cellulosum(Myxobacteria)—Production, Physico-chemical and Biological Properties,” pp. 560-563 (1996).
Giannakakou et al., J. Biol. Chem., vol. 27, “Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization,” pp. 17118-17125 (1997).
Grever et al., Seminars in Oncol., vol. 19(6), “The National Cancer Institute: Cancer Drug Discovery and Development Program,” pp. 622-638 (1992).
Höfle et al., Angew. Chem., vol. 108(13/14), pp. 1671-1672 (1996) (translated portion stapled to top of this article).
Jordan et al., Med. Res. Rev., vol. 18, “Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle,” pp. 259-295 (1998).
Kowalski et al., J. Biol. Chem., vol. 272(4), “Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)”, pp. 2534-2541 (1997).
May et al., Chemical Communication, “Total synthesis of (--)-epothilone B,” pp. 1597-1598 (1998).
Moasser et al., Proc. Natl. Acad. Sci. USA, vol. 95, “Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones,” pp. 1369-1374 (1998).
Mühlradt et al., Cancer Research, vol. 57, “Epothilone B Stabilizes Microtubuli of Macrophages Like Taxol without Showing Taxol-like Endotoxin Activity,” pp. 3344-3346 (1997).
Nicolaou et al., Nature, vol. 387, “Synthesis of epothilones A and B in solid and solution phase,” pp. 268-272 (1997).
Nicolaou et al., Angew. Chem. Int. Ed., vol. 36(19), “Designed Epothilones: Combinatorial Synthesis, Tubulin Assembly Properties, and Cytotoxic Action against Taxol-Resistant Tumor Cells,” pp. 2097-2103 (1997).
Nicolaou et al., Angew. Chem. Int. Ed., vol. 37, “Chemical Biology of Epothilones,” pp. 2014-2045 (1998).
Nicolaou et al., Chemistry & Biology, vol. 5(7), “Synthesis and biological properties of C12, 13-cyclopropyl-epothilone A and related epothilones,” pp. 365-372 (1998).
Su et al., Angew. Chem. Int. Ed., vol. 36(7), “Total Synthesis of (--)-Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure-Activity Relationships of the Epothilones,” pp. 757-759 (1997).
Su et al., Angew. Chem. Int. Ed., vol. 36(19), “Structure-Activity Relationships of Epothilones and the First In Vivo Comparison with Paclitaxel,” pp. 2093-2096 (1997).
Wartmann et al., Proceedings of the Amer. Assn. for Cancer Res., New Orleans, Mar. 28-31, 1998., vol. 39, “In vitro and in vivo activity profile of the microtubule-stabilizing agents epothilone A and B,” p. 163, Abstract #1118 (1998).
Chou et al., Proceedings of the Amer. Assn. for Cancer Res., New Orleans, Mar. 28-31, 1998, vol. 39, “Pharmacologic comparison of epothilones and taxol,” pp. 163-164, Abstract #1119 (1998).
Wolff et al., Int. J. Oncol., vol. 11, “Epothilone A induces apoptosis in neuroblastoma cells with multiple mechanisms of drug resistance,” pp. 123-126 (1997).
Fojo et al., Cancer Res., vol. 45, “Reduced Drug Accumulation in Multiply Drug-resistant Human KB Carcinoma Cell Lines,” pp. 3002-3007 (1985).
Akiyama et al., Somatic Cell and Molecular Genetics, vol. 11, No. 2. “Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs”, pp. 117-126 (1985).
Meyer et al., Int. J. Cancer, vol. 43, “A Derivative of Staurosporine (CGP 41 251) Shows Selectively for Protein Kinase C Inhibition and In Vitro Anti-Proliferative as well as In Vivo Anti-Tumor Activity”, pp. 851-856 (1989).
Bradley D., Drug Discovery Today, vol. 2(3), “Race to displace Taxol,” pp. 87-88 (1997).
Cowden C., and Paterson, I., Nature, vol. 387, “Cancer drugs better than taxol?”, pp. 238-239 (1997).
Höfle G. et al., Angew. Chem. Int. Ed. Engl., vol. 35 (13/14)—, “Epothilone A and B—Novwel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution,” pp. 1567-1569 (1996).
König J., Pharmazeutische Zeitung, vol. 142 (8) “Epothilon, ein neuer Wirkstoff gegen Krebs?” p. 35 (English translation attached).
Mann J., Nature, vol. 385, “Myxobacterial bounty,” p. 117 (1997).
U.S. Appl. No. 11/089,269, filed Mar. 24, 2005, O'Reilly et al.
Avila, “The use of microtubule poisons on tumor cells,” Cancer Journal, 10(6):315-318 (1997).
Blasius et al., “Für Wissenschaft und Praxis,” Deutsche Apotheker Zeitung, 138(46):54-69 (1998).
Blum et al., “In vivo metabolism of epothilone

Affiliated with

Also associated with

Rating

Cancer treatment with epothilones does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer treatment with epothilones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment with epothilones will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2620957